Press release
Bevacizumab Biosimilars Market Analysis By Top Players And Regional Outlook 2023 - 2032 | Hetero Drugs Ltd., Amgen Inc., Biocon Ltd., Mylan Inc., BioXpress Therapeutics SA
Bevacizumab Biosimilars Market Research
The Business Research Company's Bevacizumab Biosimilars Global Market Report 2023 identifies the rising prevalence of cancer cases as the major driver for the Bevacizumab Biosimilars market's growth in the forecast period. Cancer incidence refers to the number of new cancer cases in a specific population for a given period. Bevacizumab is a biologic that inhibits tumor angiogenesis, which can lead to tumor shrinkage and growth inhibition, and it is comparable to reference biologics in terms of efficacy and safety in treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, in 2021, According to the American cancer society, 1.8 million new cancer cases were diagnosed in 2020.
The global bevacizumab biosimilars market size is expected to grow from $1.31 billion in 2022 to $1.43 billion in 2023 at a compound annual growth rate (CAGR) of 9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global bevacizumab biosimilars market size is expected to reach $1.93 billion in 2027 at a CAGR of 7.9%.
Download Free Sample Of Bevacizumab Biosimilars Market Report
https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp
Major competitors in the Bevacizumab Biosimilars market are Hetero Drugs Ltd., Amgen Inc., Biocon Ltd., Mylan Inc., BioXpress Therapeutics SA, Celltrion Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Samsung Bioepis Co. Ltd., mAbxience SA, Aurobindo Pharma Ltd., Abbvie Inc., Allergan Plc., Reliance lifesciences Pvt. Ltd., Beaconpharma Ltd., Celgene Corporation Co. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., F. Hoffmann-La Roche Ltd., and Genentech Inc.
A key trend in the Bevacizumab Biosimilars market includes the product innovation has emerged. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in May 2022, Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, launched a biosimilar called Abevmy® (bevacizumab), which is a biosimilar similar to Roche's Avastin® (bevacizumab).
Read More On The Global Bevacizumab Biosimilars Market Report Here:
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
The Bevacizumab Biosimilars market is segmented -
By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products
By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer
By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the Bevacizumab Biosimilars market.
The Business Research Company's "Global Bevacizumab Biosimilars Market Report 2023" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.
Explore Buying Options For The Bevacizumab Biosimilars Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10848
The Table Of Content For The Bevacizumab Biosimilars Market Include:
1. Executive Summary
2. Bevacizumab Biosimilars Market Characteristics
3. Bevacizumab Biosimilars Market Trends And Strategies
4. Bevacizumab Biosimilars Market - Macro Economic Scenario
5. Bevacizumab Biosimilars Market Size And Growth
……
26. Africa Bevacizumab Biosimilars Market
27. Bevacizumab Biosimilars Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Bevacizumab Biosimilars Market
29. Bevacizumab Biosimilars Market Future Outlook and Potential Analysis
30. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.
Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bevacizumab Biosimilars Market Analysis By Top Players And Regional Outlook 2023 - 2032 | Hetero Drugs Ltd., Amgen Inc., Biocon Ltd., Mylan Inc., BioXpress Therapeutics SA here
News-ID: 3168181 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Bevacizumab
Key Trends Reshaping the Bevacizumab Biosimilars Market: Advancing Product Innov …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Bevacizumab Biosimilars Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, the bevacizumab biosimilars market has been experiencing robust growth. The market, which was valued at $1.53 billion in 2024, will surge to $1.64 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Global Bevacizumab Biosimilars Market Outlook 2025-2034: Trends, Innovations, An …
The Bevacizumab Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Bevacizumab Biosimilars Market Size During the Forecast Period?
There has been a robust expansion in the market size of bevacizumab biosimilars in the past few years. The market is projected to…
Key Trend Reshaping the Bevacizumab Biosimilars Market in 2025: Advancing Produc …
What combination of drivers is leading to accelerated growth in the bevacizumab biosimilars market?
An increasing number of cancer cases is anticipated to fuel the expansion of the bevacizumab biosimilar market in the future. The term cancer incidence refers to the tally of new cancer diagnoses within a certain demographic over a specified timeframe. Bevacizumab is a biologic agent that hinders tumor angiogenesis, resulting in the potential reduction and inhibition of…
Rising Cancer Prevalence Drives Growth Of The Avastin (Bevacizumab) Market: Majo …
What Are the Market Size and Growth Forecast for the Avastin (Bevacizumab) Market?
In recent times, the market size for avastin (bevacizumab) has seen significant growth. A projection predicts that the value will increase from $7,251.35 million in 2024 to $7,819.19 million in 2025, growing at a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the historic period include the approval from regulatory bodies, an increase…
Rising Cancer Prevalence Drives Growth Of The Avastin (Bevacizumab) Market: Majo …
What Are the Market Size and Growth Forecast for the Avastin (Bevacizumab) Market?
In recent times, the market size for avastin (bevacizumab) has seen significant growth. A projection predicts that the value will increase from $7,251.35 million in 2024 to $7,819.19 million in 2025, growing at a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the historic period include the approval from regulatory bodies, an increase…
2020-2025: Bevacizumab Biosimilar Market Report Covers Growing Strategies Used B …
Business Industry Reports Research has recently announced a report on Global Bevacizumab Biosimilar Market based on the Healthcare Industry. The Bevacizumab Biosimilar Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2025.
Global Bevacizumab Biosimilar Market overview:
A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are…
